The CF Trust Blog: Orkambi in the UK: Our work begins
The CF Trust Blog: Orkambi in the UK: Our work begins Tuesday, 2 June 2015 Orkambi in the UK: Our work begins Following the Trust taking part in a meeting with National Institute for Health and Care Excellence (NICE) to discuss the process for appraising the new cystic fibrosis drug Orkambi, Chief Executive Ed Owen, who attended to represent the Trust, looks a the road ahead for getting the combination therapy to people with CF. The news two weeks ago that Vertexs latest drug, Orkambi (a combination of ivacaftor or Kalydeco and lumacaftor), has demonstrated impact for the most common mutation of cystic fibrosis was greeted with enthusiasm and excitement.
Following the Trust taking part in a meeting with National Institute for Health and Care Excellence (NICE) to discuss the process for appr...